iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Ben Forbes und 16 weiteren Autor:innen. Beteiligte Einrichtung: King's College London, London SE1 9NH, U.K. Hauptthemen laut MEDLINE: Biopharmaceutics, Drug Development. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Product Quality Research Institute.
Abstract (Originalsprache)
This is the fourth paper in a series describing an inhalation biopharmaceutics classification system (iBCS), an initiative supported by the Product Quality Research Institute. The paper examines the application of the inhalation Biopharmaceutics Classification System (iBCS) through the drug discovery, development, and postapproval phases for orally inhaled drug products (OIDP) and for the development of generic OIDPs. We consider the implication of the iBCS class in terms of product performance and identify the practical gaps that must be filled to enable the classification system to be adopted into day-to-day practice. Consideration is given to the critical experimental data required and the methods for their generation with a focus on: (i) dose to the lungs, (ii) drug solubility in relevant media and methods to model the dissolution of respirable formulations, and (iii) pulmonary drug permeability. As described in three prior publications, the iBCS was developed to classify inhaled drugs based on physicochemical and biorelevant product attributes in a manner that will allow formulators and discovery chemists to identify and mitigate product development risks. It was not established to enable in vitro determination of bioequivalence between orally inhaled drug products. However, once analytical methods are in place to correctly classify inhaled drugs, the system has the potential to provide an understanding of the development risks associated with both establishing bioequivalence between two drug products and enabling postapproval changes based on product iBCS class.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- King's College London, London SE1 9NH, U.K.
- Emmace Consulting, SE-223 63 Lund, Sweden.
- Eisai, Woodcliff Lake, New Jersey 07677, United States.
- Aerogen Pharma, San Mateo, California 94402, United States.
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin D02 PN40, Ireland.
- JDP Pharma Consulting, San Carlos, California 94070, United States.
ORCID-Profile: Ben Forbes, Per Bäckman, Carsten Ehrhardt, Jayne E Hastedt, Philip J Kuehl
Förderung
- Product Quality Research Institute
Zitieren
APA
Forbes, B., Bäckman, P., Cabal, A., Clark, A., Ehrhardt, C., Hastedt, J. E., Hickey, A. J., Hochhaus, G., Jiang, W., Kassinos, S., Kuehl, P. J., Olsson, B., Prime, D., Son, Y. J., Teague, S., Tehler, U., & Wylie, J. (2025). iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01534
Vancouver
Forbes B, Bäckman P, Cabal A, Clark A, Ehrhardt C, Hastedt JE, et al. iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01534
BibTeX
@article{Forbes2025,
author = {Forbes, Ben and Bäckman, Per and Cabal, Antonio and Clark, Andy and Ehrhardt, Carsten and Hastedt, Jayne E and Hickey, Anthony J and Hochhaus, Guenther and Jiang, Wenlei and Kassinos, Stavros and Kuehl, Philip J and Olsson, Bo and Prime, David and Son, Yoen-Ju and Teague, Simon and Tehler, Ulrika and Wylie, Jennifer},
title = {iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01534}
}
EUVIMED